Wednesday, July 30, 2014 Last update: 4:03 PM - All Company Technology News Since 1996

Eleven Biotherapeutics to Present at March Healthcare Conferences

Companies mentioned in this article: Eleven Biotherapeutics

CAMBRIDGE, Mass. -- (BUSINESS WIRE) -- Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that Abbie Celniker, Ph.D., Eleven’s President and CEO, is scheduled to present at the following healthcare conferences during March 2014.

  • Cowen 34th Annual Healthcare Conference in Boston on Wednesday, March 5, 2014 at 8:40 a.m. ET.
  • 21st Annual Future Leaders in the Biotech Industry Conference in New York on Friday, March 28, 2014 at 9:00 a.m. ET. Interested parties may access a live webcast of this presentation by visiting the Eleven Biotherapeutics website at The webcast will be archived on the Eleven Biotherapeutics website following the event for one week.

About Eleven Biotherapeutics

Eleven Biotherapeutics (NASDAQ:EBIO) is a clinical-stage biopharmaceutical company with a proprietary protein engineering platform, called AMP-Rx, that it applies to the discovery and development of protein therapeutics to treat diseases of the eye. The company’s therapeutic approach is based on the role of cytokines in diseases of the eye, the company’s understanding of the structural biology of cytokines and the company’s ability to rationally design and engineer proteins to modulate the effects of cytokines. Cytokines are cell signaling molecules found in the body that can have important inflammatory effects.

Copyright © Business Wire 2014

Eleven Biotherapeutics
Cameron Wheeler, PhD, 617-858-0927
The Yates Network
Gina Nugent, 617-460-3579